Form 4: Anika Therapeutics Director Sheryl L. Conley Granted Over 14,000 Restricted Stock Units

Anika Therapeutics, Inc. Director Sheryl L. Conley was granted 14,164 restricted stock units (RSUs) on June 20, 2025, as part of her compensation, aligning her interests with shareholders.

Summary

• Sheryl L. Conley, a Director at Anika Therapeutics, Inc. (ANIK), acquired 14,164 shares of common stock on June 20, 2025.
• The acquisition was a grant of Restricted Stock Units (RSUs) at a price of $0 per share.
• Each RSU represents a contingent right to receive one share of the Company's common stock.
• Following this transaction, Ms. Conley beneficially owns 42,568 shares of Anika Therapeutics common stock.
• The RSUs are scheduled to vest in full on the earlier of the Company's 2026 annual meeting of stockholders or June 20, 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive as it represents a standard compensation event for a director, aligning their interests with the company's performance through equity ownership. It does not indicate any negative operational or financial news.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Sheryl L. Conley aligns her financial interests directly with the long-term performance and shareholder value of Anika Therapeutics, Inc.
• RSUs are a common form of equity compensation, indicating standard corporate governance practices for director remuneration.

Future Outlook

The granted Restricted Stock Units (RSUs) are set to vest in full on the earlier of the 2026 annual meeting of Anika Therapeutics' stockholders or June 20, 2026, indicating a future milestone for the director's compensation.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a standard practice in the biotechnology and medical technology industries for executive and board compensation, aiming to incentivize long-term performance and align leadership interests with shareholder returns.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term company value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 14,164 Restricted Stock Units (RSUs) will vest in full on the earlier of the 2026 annual meeting of Anika Therapeutics' stockholders or June 20, 2026.

Key Dates

Keywords

Anika Therapeutics, ANIK, Restricted Stock Units, RSU, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Beneficial Ownership